Does 7-OH Actually Meet the Legal Standard for Emergency Scheduling?
he DEA doesn't just have to believe 7-OH is dangerous — it has to meet a specific legal standard to schedule it this way, and the record it built doesn't clear that bar on its own terms. A two-year Schedule I placement, no judicial review, and a "good cause" exception invoked against a product sold openly for years. This piece reads the DEA's own notice, sentence by sentence, and shows where the case falls apart.
If 7-OH Is "Synthetic," Where's the Patent? The Contradiction at the Heart of the Ban
Regulators keep calling 7-OH a "synthetic opioid." But you can't patent a natural compound, and no one holds a patent on 7-OH — because it's a naturally occurring plant alkaloid. Meanwhile, pharmaceutical companies are patenting genuinely synthetic versions to sell. It can't be synthetic enough to ban and natural enough to be unpatentable. The contradiction, exposed.
The American Kratom Association Is Calling 7-OH a "Synthetic Opioid." It Isn't. And They Know It.
When the DEA moved to schedule 7-OH, the American Kratom Association cheered — and repeated the claim that 7-OH is a dangerous synthetic opioid. It isn't. It's a naturally occurring kratom alkaloid, present in every batch of leaf AKA's own members sell. Here's why their "protect the leaf, sacrifice 7-OH" strategy is scientifically wrong, strategically self-defeating, and who it actually protects.
DEA Files Notice of Intent to Schedule 7-Hydroxymitragynine: What It Actually Means — and Who Gets Hurt
DEA filed a notice of intent July 1, 2026 to temporarily schedule 7-hydroxymitragynine. The comment period closes July 31. Here's what was actually filed, what the threshold means, and who gets hurt.